STOCK TITAN
  1. Home
  2. Sec-filings
  3. ADXN
  4. [Form 3] Addex Therapeutics Ltd. Initial Statement of Beneficial Ownership

Addex Therapeutics (ADXN) director discloses share and option holdings

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

Addex Therapeutics Ltd. director Jason Raleigh Nunn filed an initial ownership report showing his existing stake in the company. He directly holds 219,561 shares of Common Stock listed on SIX Swiss Exchange and a stock option covering 50,000 shares of Common Stock.

The stock options have an exercise price of $0.0640 per share, become exercisable in equal monthly installments over a four-year period beginning on the exercise start date of January 8, 2024, and expire on January 7, 2034. The exercise price is reported in U.S. dollars based on a stated CHF-to-USD exchange rate.

Positive

  • None.

Negative

  • None.
Insider Nunn Jason Raleigh
Role Director
Type Security Shares Price Value
holding Stock-option (Right to call) -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Stock-option (Right to call) — 50,000 shares (Direct); Common Stock — 219,561 shares (Direct)
Footnotes (1)
  1. Represents 219,561 shares of Common Stock listed on SIX Swiss Exchange. The stock-options vest on equal monthly installments over a 4-year period beginning of the exercisable date. Each stock-option grants to right to purchase one ADXN share listed on SIX Swiss Exchange. The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2769 per CHF 1.00 as of March 12, 2026.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding Insider Trading Forms →
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Nunn Jason Raleigh
(Last)(First)(Middle)
CHEMIN DES MINES 9
(Street)
GENEVACH-1202
(City)(State)(Zip)
UNITED STATES
(Country)		2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026		3. Issuer Name and Ticker or Trading Symbol
Addex Therapeutics Ltd. [ ADXN ]
3a. Foreign Trading Symbol
[ADXN] 		5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock219,561(1)D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock-option (Right to call)01/08/2024(2)01/07/2034Common Stock50,000$0.064(3)D
Explanation of Responses:
1. Represents 219,561 shares of Common Stock listed on SIX Swiss Exchange.
2. The stock-options vest on equal monthly installments over a 4-year period beginning of the exercisable date. Each stock-option grants to right to purchase one ADXN share listed on SIX Swiss Exchange.
3. The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2769 per CHF 1.00 as of March 12, 2026.
Remarks:
Exhibit List: Exhibit 24 - Power of Attorney
/s/ Lenaic Nathanael Teyssedou by power of attorney03/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Addex Therapeutics (ADXN) director Jason Raleigh Nunn report in his Form 3?

Jason Raleigh Nunn reported his existing ownership in Addex Therapeutics, including 219,561 shares of Common Stock and stock options over 50,000 shares. This Form 3 reflects his starting position as a director rather than new market transactions.

How many Addex Therapeutics (ADXN) common shares does Jason Raleigh Nunn hold?

Jason Raleigh Nunn holds 219,561 shares of Addex Therapeutics Common Stock. A footnote specifies these shares are listed on SIX Swiss Exchange, providing clarity on where this equity position is traded and helping investors understand his direct equity exposure.

What are the terms of Jason Raleigh Nunn’s Addex Therapeutics (ADXN) stock options?

Nunn holds a stock option for 50,000 Addex Therapeutics common shares at an exercise price of $0.0640. The options vest in equal monthly installments over four years starting January 8, 2024, and expire on January 7, 2034, indicating a long-dated incentive award.

How was the Addex Therapeutics (ADXN) stock option exercise price determined in the filing?

The stock option exercise price of $0.0640 per share is reported in U.S. dollars. A footnote states it reflects conversion from Swiss francs using an exchange rate of $1.2769 per CHF 1.00 as of March 12, 2026, standardizing the disclosure for U.S. readers.

Do the reported Addex Therapeutics (ADXN) holdings indicate recent insider buying or selling?

The Form 3 lists holdings but does not show new insider buying or selling activity. Both entries are classified as holdings with unknown transaction codes, meaning the filing primarily establishes Nunn’s existing ownership position rather than recording fresh trades.